Seroxat Litigation - Report of the Committee on Safety of Medicines Expert Working Group on SSRI Antidepressants, 2004 - ‘Regulatory History’
http://the-uk-seroxat-litigation-chronicles.blogspot.com/
The much publicised Committee on Safety of Medicines (CSM) Expert Working Group (EWG) report “On the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants” published December 2004 has been haled as a victory in raising awareness about the problems associated with the drug class – which it was.
Mark Harvey of Hugh James, BBC Panorama’s Shelley Jofre, the Seroxat User Groups and Campaigners have laid claim to this as their achievement - although the drug regulatory and safety authorities were aware of the and investigating the issues of the drug class’ safety, propensity to cause suicide, dependency and withdrawal problems from the early 1990’s.
The issue of dependency associated with the SSRIs had already been discussed at European level by the Committee on Proprietary Medicinal Products (CPMP) and its Pharmacovigilance Working Party (PhVWP), in December 1998 the PhVWP decided France and Germany should further evaluate this issue resulting in a CPMP position paper published April 2000;
“The conclusion of the CSM and the CPMP was that all SSRIs are associated with withdrawal reactions; however, they are not drugs of dependence.”
on completion of the review on SSRIs drug class safety profile in relation to the dependence, withdrawal reactions and review of suicidal behaviour with SSRIs issue, a further article covering both aspects was published in 'Current Problems in Pharmacovigilance' September 2000.
As a result of the CPMP position paper (2000) product information for all SSRIs throughout Europe were changed in relation to inclusion of withdrawal reactions, UK product information for all SSRI, SNRIs were updated accordingly.
The following excerpt from the CSM EWG report briefly explains the history of the concerns, investigations and actions, early 1990’s to date of it’s publication December 2004
“2 REGULATORY HISTORY
This chapter outlines the regulatory history of SSRIs in the UK with particular referenceto the two mains areas of concern - withdrawal reactions and suicidal behaviour.
2.1 Withdrawal reactions in association with SSRIs
It has been known for many years that symptoms can occur on the withdrawal of antidepressants. Syndromes occurring on the withdrawal of tricyclic antidepressants (TCAs) have been defined and severe reactions have been noted on the withdrawal of monoamine oxidase inhibitors (MAOIs)[1]. Since the early 1990s, it has become clear that the SSRIs can also be associated with withdrawal reactions, although different SSRIs appear to cause withdrawal reactions to different extents[2]. The greatest number of spontaneous reports of withdrawal reactions have been associated with paroxetine. An article in 'Current Problems in Pharmacovigilance' in 1993 highlighted the risk of withdrawal reactions associated with paroxetine[3].
In late 1997, an article entitled 'The Antidepressant Web' by Charles Medawar raised concern that some people may become dependent on SSRIs[4]; this prompted a review of withdrawal reactions and dependence with these drugs. The related antidepressants venlafaxine and nefazodone (which is no longer marketed within Europe) were also included in the review. The CSM considered this issue in early 1998.
The issue was also discussed at European level by the Committee on Proprietary Medicinal Products (CPMP) and its Pharmacovigilance Working Party (PhVWP). At the December 1998 meeting of the PhVWP it was decided that France and Germany should carry out further evaluation of the issue of dependence associated with the SSRIs. The outcome of this review was a CPMP position paper which was published in April 2000[5].
The conclusion of the CSM and the CPMP was that all SSRIs are associated with withdrawal reactions; however, they are not drugs of dependence. Following the completion of a class review of the safety profile of SSRIs and a review of suicidal behaviour with SSRIs, a further article covering these aspects and the issue of withdrawal reactions was published in 'Current Problems in Pharmacovigilance' in September 2000[6].
The CPMP position paper (2000) contained key principles in relation to withdrawal reactions for inclusion in the product information for all SSRIs throughout Europe. The UK product information for all SSRIs and venlafaxine was updated accordingly.
Concern about withdrawal reactions with SSRIs continued and more recently has focused primarily on paroxetine. The BBC's Panorama programmes in October 2002 and May 2003 highlighted the level of public concern.”
The issue of all drugs in the SSRI, SNRI class causing dependency or being addictive had been addressed in the UK and Europe, both the CSM and CPMP had opined that the drugs, including seroxat did not meet the World Health Organisation (WHO) criteria for addiction by April 2000.
This opinion was not changed by the CSM EWG investigation as described in the earlier post “The “Addiction” Issue & Hugh James’ need to change the Patient Information Leaflet (PIL)” that can be found here.
The closing paragraph of the above excerpt draws attention to the recent (2002 to 2004) primary focus being placed on paroxetine (Seroxat) and the “BBC's Panorama programmes in October 2002 and May 2003 highlighted the level of public concern”.
Although the CSM EWG report is quite explicitly centred on all SSRIs and venlafaxine (Efexor) - the media, Hugh James’ Mark Harvey, the Seroxat User Group and Seroxat Campaigners’ selective interpretation of this statement is that Seroxat is the worse drug in the class because recent (2002 - 2004) concern about all drugs had shifted and “focused primarily on paroxetine”; However, would be more reasonable to say the drug Seroxats’ notoriety was generated by the “level” of adverse media coverage and the BBC Panorama’s two Seroxat focused programs?
CMS EWG Quote References
1 - Lejoyeux M et al (1996) ‘Antidepressant withdrawal syndromes’ CNS Drugs 5: 278-292.
2 - Stoukides J A & Stoukides C A (1991) ‘Extrapyramidal symptoms upon discontinuation of fluoxetine (letter).’ Am J Psychiatry 148(9): 1263.
3 - MCA/CSM (1993) Current Problems in Pharmacovigilance 19
4 - Medawar C (1997) ‘The Antidepressant Web.’ Int J Risk Safety Med 10: 75-126.
5 - http://www.emea.eu.int/pdfs/human/press/pp/277599en.pdf
6 - MCA/CSM (2000) Current Problems in Pharmacovigilance 26
7 - Teicher MH et al (1990) ‘Emergence of intense suicidal preoccupation during fluoxetine treatment.’ Am J Psychiatry 147:207-210
8 - MCA/CSM (1992) Current Problems in Pharmacovigilance 18.
9 - Healy D (1999): ‘A Failure to Warn [editorial].’ Int J Risk Safety Med 12: 151-6
10 - Lane RM (1998). ‘SSRI-induced extrapyramidal side effects and akathisia: implications for treatment.’ J Psychopharmacology. 12: 192-214.
Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Sunday, 14 November 2010
Tobin v. SmithKline - Schell first suffered from his nerves in the mid-1980s
Tobin v. SmithKline
In February 1998, Donald Schell, a 60-year-old living in Gillette, Wyoming, became withdrawn and began to complain to his wife Rita of difficulty in sleeping. Schell first suffered from his nerves in the mid-1980s, with approximately five subsequent nervous episodes centred on work stressors or bereavements. Don and Rita appeared to most of those who knew them to be a close couple. They were married for 37 years. They had two children, Michael and Deborah. Deborah married Tim Tobin in 1992 and in 1997 she gave birth to the Schell’s first grandchild, Alyssa. Deborah and Alyssa, now nine months old, came down from Billings, Montana to stay for a few days with Don and Rita in February 1998.
Don’s means of handling his nerves was to take time off work, as he could easily get someone to deputize for him. He went for walks with his wife and spent time talking with friends or with Tim, if he was around, in addition to taking care of his diet. He had got on well with a Dr. Suhany in 1990, so if he remained low after a week or two, either Rita or Don himself would suggest going along to see the doctor. Suhany had first put Schell on Prozac and noted that it made him tense, anxious and jittery, despite the fact that he was on several antidotes such as Inderal, Ativan, and Desyrel. Suhany stopped Prozac and put Schell on imipramine, to which he responded rapidly.[lxxix] What Suhany didn’t know was that Schell might have even been hallucinating while on Prozac. Having responded to imipramine in 1990, in two further brief episodes in the 1990s Schell was put on tricyclic antidepressants and again responded rapidly.
In February of 1998, when Schell began to complain about his sleep, he and Rita went to see a primary care physician, Dr. Patel. Dr. Patel did a thorough examination, which included rating scales that indicated Schell’s main difficulty was poor sleep and that he felt hopeful about the future and thought well of himself. Patel diagnosed an anxiety state and, unaware of the significance of a prior adverse response to Prozac, put Schell on Paxil, without any covering antidotes. Forty-eight hours later Don Schell put three bullets from two different guns through Rita’s head, and then through Deborah and Alyssa’s heads before shooting himself.
After more than a year in a mental wilderness, Tim Tobin sought out Andy Vickery and took an action for wrongful death against SmithKline Beecham, then in the process of becoming Glaxo-SmithKline, the worlds largest pharmaceutical company. I was retained in the case.
http://webcache.googleusercontent.com/search?q=cache:VmoUVgyT6gAJ:www.healyprozac.com/Book/Chapter10.doc+donald+schell+depressed&cd=6&hl=en&ct=clnk&gl=uk
In February 1998, Donald Schell, a 60-year-old living in Gillette, Wyoming, became withdrawn and began to complain to his wife Rita of difficulty in sleeping. Schell first suffered from his nerves in the mid-1980s, with approximately five subsequent nervous episodes centred on work stressors or bereavements. Don and Rita appeared to most of those who knew them to be a close couple. They were married for 37 years. They had two children, Michael and Deborah. Deborah married Tim Tobin in 1992 and in 1997 she gave birth to the Schell’s first grandchild, Alyssa. Deborah and Alyssa, now nine months old, came down from Billings, Montana to stay for a few days with Don and Rita in February 1998.
Don’s means of handling his nerves was to take time off work, as he could easily get someone to deputize for him. He went for walks with his wife and spent time talking with friends or with Tim, if he was around, in addition to taking care of his diet. He had got on well with a Dr. Suhany in 1990, so if he remained low after a week or two, either Rita or Don himself would suggest going along to see the doctor. Suhany had first put Schell on Prozac and noted that it made him tense, anxious and jittery, despite the fact that he was on several antidotes such as Inderal, Ativan, and Desyrel. Suhany stopped Prozac and put Schell on imipramine, to which he responded rapidly.[lxxix] What Suhany didn’t know was that Schell might have even been hallucinating while on Prozac. Having responded to imipramine in 1990, in two further brief episodes in the 1990s Schell was put on tricyclic antidepressants and again responded rapidly.
In February of 1998, when Schell began to complain about his sleep, he and Rita went to see a primary care physician, Dr. Patel. Dr. Patel did a thorough examination, which included rating scales that indicated Schell’s main difficulty was poor sleep and that he felt hopeful about the future and thought well of himself. Patel diagnosed an anxiety state and, unaware of the significance of a prior adverse response to Prozac, put Schell on Paxil, without any covering antidotes. Forty-eight hours later Don Schell put three bullets from two different guns through Rita’s head, and then through Deborah and Alyssa’s heads before shooting himself.
After more than a year in a mental wilderness, Tim Tobin sought out Andy Vickery and took an action for wrongful death against SmithKline Beecham, then in the process of becoming Glaxo-SmithKline, the worlds largest pharmaceutical company. I was retained in the case.
http://webcache.googleusercontent.com/search?q=cache:VmoUVgyT6gAJ:www.healyprozac.com/Book/Chapter10.doc+donald+schell+depressed&cd=6&hl=en&ct=clnk&gl=uk
Saturday, 13 November 2010
40 deaths linked to child vaccines - MHRA confirm - source Sunday Times
40 deaths linked to child vaccines over seven years
Childhood vaccinations are suspected to have left two children with
brain injuries and caused 1,500 other neurological reactions
Sarah-Kate Templeton, Health Editor
Published: 24 October 2010
Forty children are suspected to have died as a result of receiving
routine vaccines in the past seven years.
Childhood vaccinations are also suspected of having left two young
children with brain injuries and caused more than 1,500 other
neurological reactions, including 11 cases of inflammation of the
brain, 13 cases of epilepsy and a coma.
The data, disclosed by the Medicines and Healthcare products
Regulatory Authority (MHRA) following a request by The Sunday Times
under the Freedom of Information Act, shows that, since 2003, there
have been more than 2,100 serious adverse reactions to childhood
vaccines, some of which were life-threatening.
Fifteen injections are given routinely to young children as part of
the governments vaccination programme. They offer protection against
diseases such as polio, diphtheria, mumps and measles.
The MHRA says the deaths and neurological reactions should be seen in
the context of the 90m doses of childhood vaccines which have been
given since 2003.
Details of the suspected deaths and neurological problems have been
released just two months after a legal ruling forced the government to
accept that its vaccination programme had left a baby severely brain
damaged.
Thirteen years after first refusing to acknowledge that Robert
Fletcher, now 18, had been left severely brain damaged by the MMR
vaccine for measles, mumps and rubella, the government was forced to
pay him compensation.
Roberts mother, Jackie, who founded Jabs, a support group for
families with vaccine-damaged children, said: It is generally
accepted within the medical profession that only about 10% of
suspected adverse reactions get put forward in the correct way. It is
accepted by the Department of Health that the full scale of the
problem is far greater than these statistics show.
Jake Dukes, 18, from Weymouth, Dorset, was left severely brain damaged
by the whooping cough vaccine, which he received when he was two
months old. He has the mental age of a toddler, is incontinent and
uses a wheelchair. He was awarded £91,500 under the governments
vaccine damage payment scheme.
The family of George Fisher are convinced that the MMR vaccine
contributed to the death of their 18-month-old son. He died 10 days
after being inoculated in January 2006.
His mother, Sarah, a hotel receptionist from Cheltenham,
Gloucestershire, believes that an existing illness made him
susceptible to an adverse reaction to the vaccine. Four months before
receiving the jab, George had suffered a fit brought on by a high
fever. Sarah said: George had had a bad virus. He had been very ill
and had suffered a convulsion due to his high temperature. I dont
think it was just the MMR, but I think it was a factor in his death.
Friday, 12 November 2010
Mark Harvey's firm takes legal aid funding then drops depression drug case !!!!
Mark Harvey's firm takes legal aid funding then drops depression drug case !!!!
British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions,believing that the cases would be impossible to prove.
Copyright 2004 Times Newspapers Ltd
Roaccutane.Campaigners against the drug believe that the exercise would demonstrate a strong link between use of the drug and suicide.However, a British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions, believing that the cases would be impossible to prove."About 80 or 90 claimants came forward but we had to report that we did not think the claims could be won," said Mark Harvey, now a partner in Hugh James, the solicitors in Cardiff. "You have to beable to link depression to the drug and it would be difficult to prove that it might not have arisen anyway and to eliminate other causes. Isn't depression a side effect of puberty or acne in any event?
It is going to be difficult to get the Legal Aid Board to reopen this."
Copyright 2004 Times Newspapers Ltd
British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions,believing that the cases would be impossible to prove.
Copyright 2004 Times Newspapers Ltd
Roaccutane.Campaigners against the drug believe that the exercise would demonstrate a strong link between use of the drug and suicide.However, a British firm of solicitors that received legal aid to pursue litigation against Roche five years ago has now dropped the actions, believing that the cases would be impossible to prove."About 80 or 90 claimants came forward but we had to report that we did not think the claims could be won," said Mark Harvey, now a partner in Hugh James, the solicitors in Cardiff. "You have to beable to link depression to the drug and it would be difficult to prove that it might not have arisen anyway and to eliminate other causes. Isn't depression a side effect of puberty or acne in any event?
It is going to be difficult to get the Legal Aid Board to reopen this."
Copyright 2004 Times Newspapers Ltd
Acne drug not found to increase suicide risk
People being treated for severe acne should have their mental health closely monitored, a study reports.
http://www.bbc.co.uk/news/health-11734080
But a popular acne drug was not found to increase the risk of suicide, despite previous findings.
The study of 5,700 people, in the British Medical Journal, was carried out at the Karolinska Institute, Sweden between 1980 and 2001.
Acne can have serious psychological effects, say experts.
Severe acne sufferers are commonly prescribed a drug called isotretinoin, also known as Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan.
It has been used since the 1980s to treat severe acne if a course of antibiotics does not prove effective.
But there have been reports linking isotretinoin to depression and suicidal behaviour.
So Dr Anders Sundstrom and his research team from Sweden studied suicide attempts before, during and after treatment with this drug for severe acne.
Continue reading the main story
“
Start Quote
Acne can have significant psychological effects .”
End Quote
Dr Sarah Bailey
University of Bath
They found that 128 of the 5,700 patients investigated who were taking the drug were admitted to hospital for attempted suicide.
The risk of suicide was highest within six months of ending treatment - but the researchers say this is most likely to be because patients whose acne improved following treatment were distraught if there was no improvement in their social life, rather than anything to do with the treatment itself.
They stress that attempted suicide was a rare event - the figures suggest just one person out of every 2,300 individuals taking isotretinoin will make a first suicide attempt.
Monitor patients
Dr Sundstrom said of his findings: "The underlying condition of acne is a more important factor for suicide attempts. We are not certain the drug adds anything."
Writing in an editorial in the BMJ, Australian acne experts John Sullivan and Parker Magin say that the Swedish research is important given the complexity of the issue.
"It is difficult to tease out the relation between mental health and isotretinoin because acne itself is associated with psychiatric morbidity, including depression."
They also say that the study shows GPs must closely monitor acne patients on isotretinoin.
"During and after treatment with isotretinoin (perhaps, especially, unsuccessful treatment), patients should be carefully monitored for depression and suicidal thoughts."
Dr Sarah Bailey, lecturer in the Department of Pharmacy and Pharmacology at the University of Bath, said: "This is an important paper that strengthens the view that acne itself can have significant psychological effects and that there is a low risk of suicide for some acne patients.
"However, the controversial issue of increased suicide risk with isotretinoin use is not resolved by this paper, which the authors themselves acknowledge.
"Perhaps their most interesting and novel finding is that the risk of suicide is increased AFTER treatment has stopped and therefore it is essential to continue to monitor patients carefully."
http://www.bbc.co.uk/news/health-11734080
But a popular acne drug was not found to increase the risk of suicide, despite previous findings.
The study of 5,700 people, in the British Medical Journal, was carried out at the Karolinska Institute, Sweden between 1980 and 2001.
Acne can have serious psychological effects, say experts.
Severe acne sufferers are commonly prescribed a drug called isotretinoin, also known as Roaccutane, Accutane, Amnesteem, Claravis, Clarus or Decutan.
It has been used since the 1980s to treat severe acne if a course of antibiotics does not prove effective.
But there have been reports linking isotretinoin to depression and suicidal behaviour.
So Dr Anders Sundstrom and his research team from Sweden studied suicide attempts before, during and after treatment with this drug for severe acne.
Continue reading the main story
“
Start Quote
Acne can have significant psychological effects .”
End Quote
Dr Sarah Bailey
University of Bath
They found that 128 of the 5,700 patients investigated who were taking the drug were admitted to hospital for attempted suicide.
The risk of suicide was highest within six months of ending treatment - but the researchers say this is most likely to be because patients whose acne improved following treatment were distraught if there was no improvement in their social life, rather than anything to do with the treatment itself.
They stress that attempted suicide was a rare event - the figures suggest just one person out of every 2,300 individuals taking isotretinoin will make a first suicide attempt.
Monitor patients
Dr Sundstrom said of his findings: "The underlying condition of acne is a more important factor for suicide attempts. We are not certain the drug adds anything."
Writing in an editorial in the BMJ, Australian acne experts John Sullivan and Parker Magin say that the Swedish research is important given the complexity of the issue.
"It is difficult to tease out the relation between mental health and isotretinoin because acne itself is associated with psychiatric morbidity, including depression."
They also say that the study shows GPs must closely monitor acne patients on isotretinoin.
"During and after treatment with isotretinoin (perhaps, especially, unsuccessful treatment), patients should be carefully monitored for depression and suicidal thoughts."
Dr Sarah Bailey, lecturer in the Department of Pharmacy and Pharmacology at the University of Bath, said: "This is an important paper that strengthens the view that acne itself can have significant psychological effects and that there is a low risk of suicide for some acne patients.
"However, the controversial issue of increased suicide risk with isotretinoin use is not resolved by this paper, which the authors themselves acknowledge.
"Perhaps their most interesting and novel finding is that the risk of suicide is increased AFTER treatment has stopped and therefore it is essential to continue to monitor patients carefully."
Thursday, 11 November 2010
Good Relations & Hugh James are carefully controlling Seroxat media
Litigation and individual members’ cases should not be discussed at support meetings.
Contacting the media. Please do not encourage your members to contact the media. The Group, with Hugh James and Good Relations, are co-ordinating a carefully controlled media approach. If a member of the group asks for your advice on approaching the media, please put them in touch with the committee.
Medical advice. Be careful not to give, or appear to give, medical advice.
Please do not contact any organisation or individual on behalf of the Seroxat Users Group unless you have discussed this with the committee first.
Please do not claim to represent the views of the Seroxat Users Group.
Handling the press and making statements Unless you are promoting the launch of your group, please do not contact the press. Before contacting the press about your group, it is important you contact John Wilkinson of Good Relations. His telephone number is 029 2034 4888 and his email address is jwilkinson@goodrelations.co.uk. Please advise Hugh James and the committee of your contact with the press so that they can be prepared for enquiries.
If you are contacted by a member of the press on any topic, it is important that you do not make any statement, provide information or take part in an interview without talking to John Wilkinson. Please take the journalist’s name, organisation and contact details and promise to get back to them. Do not feel pressurised to answer questions or respond immediately.
http://www.seroxatusergroup.org.uk/Documents/regionalsupport.doc
Seroxat Janice Simmons knew nothing about medical background of Seroxat issue
Andrew Isaac said Date: 2003/06/30 Mon AM 08:30:08
I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
Online donations have been drawn on by Sarah V (venn) - a large sum (from Best Magazine) was used > to pay for the website
Online donations have been drawn on by Sarah V and then Paid to myself > to cover costs I have incurred re: the group. Things like train tickets > for the protest, postage and a large sum (from Best Magazine) was used > to pay for the website. Everything is above board and documented. > > I agree that it must be very frustrating that you cannot access the > website and would also agree that from a member's perspective the delay > in getting the bank account open can be seen as unacceptable. Please > remember that we are doing this in our spare time and work very hard.
http://www.hardwicke.co.uk/barrister-profile/_/14/sarah-venn
http://bobfiddaman.blogspot.com/2010/11/charity-co-ordinator-dr-andrew-isaac.html
http://www.hardwicke.co.uk/barrister-profile/_/14/sarah-venn
http://bobfiddaman.blogspot.com/2010/11/charity-co-ordinator-dr-andrew-isaac.html
"charity co-ordinator" Dr Andrew Isaac replies - confirms seroxatUSERgroup had no bank account
> From: "Andrew Isaac" andrew@seroxatusergroup.org.uk> > Date: 2003/06/30 Mon AM 08:30:08 GMT > To: red.ordead@ntlworld.com> > Subject: RE: urgent seroxat user group > > Dear Claire, > > Many thanks for your email and I will try and answer your questions as > best I can. The Bank account was due to be opened in January this year > but, because the committee members live so far apart it meant that every > one had to send their ID to their branch so that it could then be > forwarded to the branch we wanted to open it at - my local branch! There > was an error on the form that Janice Simmons had to correct, so the form > was sent to her. > > Janice was in the process of moving and caring for her husband John who > is going through the hell of withdrawal. This lost/cost us 3mnths where > it just wasn't possible for her to get to the bank. Since then the > problem has been when Janice has gone to her branch they say they cannot > open the account and it looks as though we will all have to be in the > same place at the same time - this will be on the 10th July - and the > account will be opened then. > > Online donations have been drawn on by Sarah V and then Paid to myself > to cover costs I have incurred re: the group. Things like train tickets > for the protest, postage and a large sum (from Best Magazine) was used > to pay for the website. Everything is above board and documented. > > I agree that it must be very frustrating that you cannot access the > website and would also agree that from a member's perspective the delay > in getting the bank account open can be seen as unacceptable. Please > remember that we are doing this in our spare time and work very hard. I > realise form the perspective of people who use the message board it > looks as though Sarah does everything but that isn't the case. > > Sarah definitely had the most public exposure but we all have > contributed roughly equal amount to the running of the group. I am in > correspondence with GSK, I wrote the four papers in the info section and > I also spent a very large amount of time analysing the Patient > Information Leaflets for Seroxat from countries around the world - the > resulting document being used by the solicitors. Due to my background as > a medical student I also explain the medical aspect of things to Janice > and Sarah so that we can present ideas to the MHRA in a coherent manner. > For example, Sarah was a bit confused as to how Seroxat work at the > receptor level and I explain this like this to her. > > As to your grave concerns about the management of the group if you can > give me a list clearly giving your explicit concerns I will do my best > to address them along with the rest of the committee. > > My apologies for any distress and inconvenience that this hiccup may > have cause and rest assured that we are on to it! > > Kind regards > > Andrew
Wednesday, 10 November 2010
Sarah Venn advises me there is no bank account for me to pay funds into - Claire Doherty > Red.ordead@ntlworld.com
-----Original Message----- > From: red.ordead@ntlworld.com [mailto:red.ordead@ntlworld.com] > Sent: 30 June 2003 01:12 > To: andrew@seroxatusergroup.org.uk; ABennett@bluepumpkin.com; > trish@canutewalk.fsnet.co.uk; sarah@seroxatusergroup.org.uk; > lydia@hastingsdiving.com; charliegreig@hotmail.com > Subject: urgent seroxat user group > > Dear committee member, > I would like to donate money to the group. > Sarah Venn advises me there is no bank account for me to pay funds into > Why? > What is happening to the online donations? > Why in six months has a bank account not been opened? > It is vital to the running of the group > I have grave concerns about the groups management > Also the site has now exceeded its bandwidth so members will not be able > to access it. > > This bank account needs to be open, otherwise how can we make donations > and how can the group continue, with such limited funding. This is a > grave worry to me as the seroxat user group is my life line and many > other members too. > I can honestly say without it I wouldnt be here. > Please can you get this sorted > I look forward to your response > > Yours hopefully > Claire Doherty > Red.ordead@ntlworld.com > >
seroxatUSERgroup who lied when they claimed to be a charity - via "wayback machine"
http://web.archive.org/web/20050427235427/www.seroxatusergroup.org.uk/who_we_are.htm
Who We Are
Janice Simmons - Charity Co-Ordinator
"I am the wife of a long term Seroxat user, and therefore I'm particularly interested in those of you who have partners, family and friends that need help in understanding the problems of taking Seroxat. I know how much it can affect all members of a family, as well as the user."
Email: janice@seroxatusergroup.org.uk
Andrew Isaac - Charity Co-Ordinator
"I took Seroxat for approximately four years and despite a protracted withdrawal, I have now successfully withdrawn from the drug. I am 30 years old and am studying medicine."
Email: andrew@seroxatusergroup.org.uk
Can You Help?
We are a self funding, non profit making organisation, and hope that you may be able to make a donation towards funding our operational costs.
Who We Are
Janice Simmons - Charity Co-Ordinator
"I am the wife of a long term Seroxat user, and therefore I'm particularly interested in those of you who have partners, family and friends that need help in understanding the problems of taking Seroxat. I know how much it can affect all members of a family, as well as the user."
Email: janice@seroxatusergroup.org.uk
Andrew Isaac - Charity Co-Ordinator
"I took Seroxat for approximately four years and despite a protracted withdrawal, I have now successfully withdrawn from the drug. I am 30 years old and am studying medicine."
Email: andrew@seroxatusergroup.org.uk
Can You Help?
We are a self funding, non profit making organisation, and hope that you may be able to make a donation towards funding our operational costs.
Glaxo's Wellbutrin Class Action Lawsuit Certification Denied
Wellbutrin Class Action Lawsuit Certification Denied
Published: October 26th, 2010 • No Comments
http://www.aboutlawsuits.com/wellbutrin-class-action-lawsuit-denied-13699/
A federal judge has refused to grant certification for a Wellbutrin class action lawsuit filed on behalf of consumers who were allegedly forced to pay higher prices for the antidepressant due to GlaxoSmithKline’s attempts to keep a generic form of the medication off the market.
The class action lawsuit over Wellbutrin was brought by the Health & Welfare Plan for the Sheet Metal Workers Local 441 in Mobile, Alabama, in the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs sought class action status on behalf of all individual consumers and more than 20,000 third-parties, such as health care plans and insurers.
The lawsuit claimed that Glaxo was attempting to delay the release of generic Wellbutrin versions through frivolous patent lawsuits against generic drug makers. Earlier this month, U.S. District Judge Lawrence F. Stengel declined to give the lawsuit class action status, saying that it would be impossible for plaintiffs to prove that the class members were financially injured by Glaxo’s actions.
Stengel determined that it would be impossible to determine which customers would have exhibited brand loyalty to GlaxoSmithKline, meaning that they would continue to buy brand-name Wellbutrin even after generic versions were released. Without being able to determine who would buy generic versions and who would not, the plaintiffs do not have a class action case, he ruled.
Wellbutrin (bupropion HCI), which is manufactured by GlaxoSmithKline, was first approved by FDA as an antidepressant in December 1985. The drug was pulled a year later due to the high number of seizures associated with Wellbutrin side effects, but it was reintroduced in 1989 after federal reviewers determined that the seizures were dose specific and lowered the daily dosage of the drug.
Wellbutrin has come under closer scrutiny recently after a study published in May in the American Journal of Obstetrics & Gynecology suggested that there may be an increased risk of heart birth defects from Wellbutrin when the medication is taken during pregnancy.
Researchers found that mothers who were given Wellbutrin in their first trimester had double the chance of giving birth to a child with a congenital heart problem than mothers who did not take the drug. However, they were not able to establish a cause-and-effect relationship between the drug and the birth defects.
Published: October 26th, 2010 • No Comments
http://www.aboutlawsuits.com/wellbutrin-class-action-lawsuit-denied-13699/
A federal judge has refused to grant certification for a Wellbutrin class action lawsuit filed on behalf of consumers who were allegedly forced to pay higher prices for the antidepressant due to GlaxoSmithKline’s attempts to keep a generic form of the medication off the market.
The class action lawsuit over Wellbutrin was brought by the Health & Welfare Plan for the Sheet Metal Workers Local 441 in Mobile, Alabama, in the U.S. District Court for the Eastern District of Pennsylvania. The plaintiffs sought class action status on behalf of all individual consumers and more than 20,000 third-parties, such as health care plans and insurers.
The lawsuit claimed that Glaxo was attempting to delay the release of generic Wellbutrin versions through frivolous patent lawsuits against generic drug makers. Earlier this month, U.S. District Judge Lawrence F. Stengel declined to give the lawsuit class action status, saying that it would be impossible for plaintiffs to prove that the class members were financially injured by Glaxo’s actions.
Stengel determined that it would be impossible to determine which customers would have exhibited brand loyalty to GlaxoSmithKline, meaning that they would continue to buy brand-name Wellbutrin even after generic versions were released. Without being able to determine who would buy generic versions and who would not, the plaintiffs do not have a class action case, he ruled.
Wellbutrin (bupropion HCI), which is manufactured by GlaxoSmithKline, was first approved by FDA as an antidepressant in December 1985. The drug was pulled a year later due to the high number of seizures associated with Wellbutrin side effects, but it was reintroduced in 1989 after federal reviewers determined that the seizures were dose specific and lowered the daily dosage of the drug.
Wellbutrin has come under closer scrutiny recently after a study published in May in the American Journal of Obstetrics & Gynecology suggested that there may be an increased risk of heart birth defects from Wellbutrin when the medication is taken during pregnancy.
Researchers found that mothers who were given Wellbutrin in their first trimester had double the chance of giving birth to a child with a congenital heart problem than mothers who did not take the drug. However, they were not able to establish a cause-and-effect relationship between the drug and the birth defects.
Paxil birth defect mother became pregnant late in life - child plays volleyball and takes tae kwon do lessons
Glaxo officials contend Paxil played no role in Anna’s heart defects. They were most likely caused by genetics or the fact that her mother became pregnant late in life, Chilton Varner, a lawyer for the drugmaker, told jurors.
The deaths of Paxil animal test subjects had nothing “to do with Anna Blyth’s heart defects,” Varner said.
http://www.bloomberg.com/news/2010-11-09/glaxo-failed-to-warn-about-paxil-risks-lawyer-says-at-philadelphia-trial.html
Varner also said Anna, an honor student who plays volleyball and takes tae kwon do lessons, has suffered no lasting effects from her early heart problems.
“She is not on any heart medications and hasn’t suffered any palpitations,” Varner said. “That’s the good news in the case.”
The deaths of Paxil animal test subjects had nothing “to do with Anna Blyth’s heart defects,” Varner said.
http://www.bloomberg.com/news/2010-11-09/glaxo-failed-to-warn-about-paxil-risks-lawyer-says-at-philadelphia-trial.html
Varner also said Anna, an honor student who plays volleyball and takes tae kwon do lessons, has suffered no lasting effects from her early heart problems.
“She is not on any heart medications and hasn’t suffered any palpitations,” Varner said. “That’s the good news in the case.”
Tuesday, 9 November 2010
Baum Hedlund - Paxil / Seroxat's Donald Schell was depressed
extract
'Three-Legged Stool'
There was no question that Donald Schell was depressed. Before taking Paxil, he had been on other antidepressants including Prozac.
Furthermore, there seemed to be no other motivation for the murder-suicide. He had no obvious marital problems and clearly adored his daughter and granddaughter. So the pivotal question of the trial was: Did taking Paxil for two days - one pill each day - cause Schell to go berserk? Or did he become violent because he was already depressed?
This chicken-and-egg-type question had been at the heart of other the other antidepressant trials, as Vickery knew well. He had tried and lost a similar case - Forsyth v. Eli Lilly & Co. - in Hawaii in 1999.
"In Hawaii, I stupidly [bought into their] either/or argument: Was it the drug or the depression? Here I just focused on the drug." By doing so, he reframed the debate for the jury from, "Was it the depression or the drug?" to "Is it possible for the drug to produce a violent reaction in some people?"
http://www.baumhedlundlaw.com/media/ssri/Paxil_murder.htm
'Three-Legged Stool'
There was no question that Donald Schell was depressed. Before taking Paxil, he had been on other antidepressants including Prozac.
Furthermore, there seemed to be no other motivation for the murder-suicide. He had no obvious marital problems and clearly adored his daughter and granddaughter. So the pivotal question of the trial was: Did taking Paxil for two days - one pill each day - cause Schell to go berserk? Or did he become violent because he was already depressed?
This chicken-and-egg-type question had been at the heart of other the other antidepressant trials, as Vickery knew well. He had tried and lost a similar case - Forsyth v. Eli Lilly & Co. - in Hawaii in 1999.
"In Hawaii, I stupidly [bought into their] either/or argument: Was it the drug or the depression? Here I just focused on the drug." By doing so, he reframed the debate for the jury from, "Was it the depression or the drug?" to "Is it possible for the drug to produce a violent reaction in some people?"
http://www.baumhedlundlaw.com/media/ssri/Paxil_murder.htm
The Evidence, However, Is Clear - only 102 votes in entire year
Sarah Venn barrister in breech of Seroxat group finance rules !
Finance
1.The funds of the Group, including all donations, contributions and bequests, shall be paid into an account operated by the Committee in the name of the Group at such bank as the Committee shall decide.
2.Group funds must only be spent in furtherance of the objects and activities ancillary to the objects.
3.At least two committee members will be authorised signatories of the bank account, one of which must be the Treasurer.
4.No committee member must withdraw funds from the bank account unless there are cleared funds to cover the withdrawal.
http://www.seroxatusergroup.org.uk/Documents/rulesgroup.doc
1.The funds of the Group, including all donations, contributions and bequests, shall be paid into an account operated by the Committee in the name of the Group at such bank as the Committee shall decide.
2.Group funds must only be spent in furtherance of the objects and activities ancillary to the objects.
3.At least two committee members will be authorised signatories of the bank account, one of which must be the Treasurer.
4.No committee member must withdraw funds from the bank account unless there are cleared funds to cover the withdrawal.
http://www.seroxatusergroup.org.uk/Documents/rulesgroup.doc
Monday, 8 November 2010
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and others [2008] EWCA Civ 1086; [2008] WLR (D) 317
Devenish Nutrition Ltd v Sanofi-Aventis SA (France) and others [2008] EWCA Civ 1086; [2008] WLR (D) 317
CA: Tuckey, Arden and Longmore LJJ: 14 October 2008
http://www.lawreports.co.uk/WLRD/2008/CACiv/oct0.5.htm
--------------------------------------------------------------------------------
CA: Tuckey, Arden and Longmore LJJ: 14 October 2008
http://www.lawreports.co.uk/WLRD/2008/CACiv/oct0.5.htm
--------------------------------------------------------------------------------
Irwin Mitchell loses vitamins appeal - Class action lobby dealt body blow
Irwin Mitchell suffered a blow in the Court of Appeal last week in a case that could spell the end for US-style class actions in the UK.
http://www.thelawyer.com/class-action-lobby-dealt-body-blow-as-irwin-mitchell-loses-vitamins-appeal/135288.article
In ;2004 ;the ;firm embarked on a mission to bring the first multi-party action for damages. The case was brought against a series of vitamins companies, including Switzerland’s Hoffman-La Roche and Germany-based BASF, which had been on the receiving end of an e855m (£669.94m) fine after being found guilty of colluding on price-fixing.
Irwin ;Mitchell ;was brought ;on ;board ;to represent a number of clients from the poultry and animal feeds sector, which alleged that the activities of the companies unfairly inflated the prices they were paying for vitamins.
.The ;lead ;claimant, Devenish Nutrition, a Belfast-based supplier of pig and poultry feed, was seeking a share of the cartelists’ profits, despite being unable to prove that it had made a financial loss as a result of the cartel.
The Court of Appeal was asked to determine whether the claimants were entitled to compensatory damages, exemplary ;damages, restitutionary damages and an account of profits.
Irwin Mitchell instructed Christopher Vajda QC of Monckton Chambers and Andrew Burrows QC of Atkin Chambers to argue that compensatory damages alone would not be an adequate remedy.
The claimants argued that, if the court ruled in their favour, it would act as a deterrent against other cartelists.
In an ideal world the case would have been brought in the US, where claims such as these are seen as the key deterrent in preventing cartels from being established.
However, here in the UK, where class actions are still unusual, Irwin Mitchell was forced to go to the Court of Appeal after the claim was rejected by the High Court.
The Court of Appeal’s 14 October decision could be another nail in the coffin for the class action lobby in the UK. For several years it has been pushing for a change in UK law to allow more people to participate in class actions.
“It’s certainly the end of people trying it on,” said one senior partner close to the case. “These people seem to be encouraged by lawyers who want them to get damages for losses they haven’t suffered. This is a sensible ruling which sits within the law as it is. The judges couldn’t have done anything else.”
According to Cohen Milstein Hausfeld & Toll partner Vincent Smith, the Devenish litigation is a good example of how cases can collapse if collective claimants ;fail ;to ;act together.
Smith said: “This wasn’t an unexpected ruling – [the judges] are bound by previous precedent. What it does show is that we need to choose claimants very carefully and make sure everybody’s involved from the very beginning.”
Smith said the case highlighted an urgent need for a framework on which to bring class actions.
“The Government is expected to respond to the CJC recommendations on class actions shortly and we expect it to come out in favour of the proposals,” he added.
To some extent the ruling recognises that changes are afoot in the class action arena. Yet Mr Justice Longmore pointed out that the court cannot act alone.
Longmore J, who sat alongside Mr Justice Tuckey and Lady Justice Arden, said: “The only real argument in favour of an order for an account of profits is the argument of policy that cartels are a notorious evil and the civil courts should in some way provide an incentive for their eradication by making such an order.
“But it doesn’t seem to me to be right for the courts to take this step on their own initiative.
“Neither the law of restitution nor the law of damages is in the business of transferring monetary gains from one undeserving recipient to another undeserving recipient, even if the former has acted illegally while the latter has not.”
With this single sentence, Longmore J must have shaken the confidence of every claimant lawyer looking to bring a class action.
“I think the class action lobby are on a hiding to nothing in the UK court,” said one litigation partner. “These are claimants who’ve suffered no actual loss – why should they be entitled to damages?”
But Irwin Mitchell’s lead partner on the case Jeremy Marshall is now planning to seek leave to appeal to the House of Lords. “This isn’t yet over, and the Court of Appeal’s given us the inkling that this should go to the Law Lords,” Marshall said.
It is understood that Irwin Mitchell is working on a contingency fee basis and therefore has a lot riding on the success of this case. If the firm wins in the Lords it will certainly be able to say that it won against the odds.
Claimant lawyers have for some time been calling on the Government to improve access to justice by modifying the class action framework and allowing more people to participate. Yet at every corner the lobby is curtailed by current UK case law. Only the case against the BA-Virgin cartel has been successful and that was largely because it was first brought in the US.
And while the defendant has the cash to pay for powerful lawyers and the claimant still scratches around for suitable funding, the situation will remain.
http://www.thelawyer.com/class-action-lobby-dealt-body-blow-as-irwin-mitchell-loses-vitamins-appeal/135288.article
In ;2004 ;the ;firm embarked on a mission to bring the first multi-party action for damages. The case was brought against a series of vitamins companies, including Switzerland’s Hoffman-La Roche and Germany-based BASF, which had been on the receiving end of an e855m (£669.94m) fine after being found guilty of colluding on price-fixing.
Irwin ;Mitchell ;was brought ;on ;board ;to represent a number of clients from the poultry and animal feeds sector, which alleged that the activities of the companies unfairly inflated the prices they were paying for vitamins.
.The ;lead ;claimant, Devenish Nutrition, a Belfast-based supplier of pig and poultry feed, was seeking a share of the cartelists’ profits, despite being unable to prove that it had made a financial loss as a result of the cartel.
The Court of Appeal was asked to determine whether the claimants were entitled to compensatory damages, exemplary ;damages, restitutionary damages and an account of profits.
Irwin Mitchell instructed Christopher Vajda QC of Monckton Chambers and Andrew Burrows QC of Atkin Chambers to argue that compensatory damages alone would not be an adequate remedy.
The claimants argued that, if the court ruled in their favour, it would act as a deterrent against other cartelists.
In an ideal world the case would have been brought in the US, where claims such as these are seen as the key deterrent in preventing cartels from being established.
However, here in the UK, where class actions are still unusual, Irwin Mitchell was forced to go to the Court of Appeal after the claim was rejected by the High Court.
The Court of Appeal’s 14 October decision could be another nail in the coffin for the class action lobby in the UK. For several years it has been pushing for a change in UK law to allow more people to participate in class actions.
“It’s certainly the end of people trying it on,” said one senior partner close to the case. “These people seem to be encouraged by lawyers who want them to get damages for losses they haven’t suffered. This is a sensible ruling which sits within the law as it is. The judges couldn’t have done anything else.”
According to Cohen Milstein Hausfeld & Toll partner Vincent Smith, the Devenish litigation is a good example of how cases can collapse if collective claimants ;fail ;to ;act together.
Smith said: “This wasn’t an unexpected ruling – [the judges] are bound by previous precedent. What it does show is that we need to choose claimants very carefully and make sure everybody’s involved from the very beginning.”
Smith said the case highlighted an urgent need for a framework on which to bring class actions.
“The Government is expected to respond to the CJC recommendations on class actions shortly and we expect it to come out in favour of the proposals,” he added.
To some extent the ruling recognises that changes are afoot in the class action arena. Yet Mr Justice Longmore pointed out that the court cannot act alone.
Longmore J, who sat alongside Mr Justice Tuckey and Lady Justice Arden, said: “The only real argument in favour of an order for an account of profits is the argument of policy that cartels are a notorious evil and the civil courts should in some way provide an incentive for their eradication by making such an order.
“But it doesn’t seem to me to be right for the courts to take this step on their own initiative.
“Neither the law of restitution nor the law of damages is in the business of transferring monetary gains from one undeserving recipient to another undeserving recipient, even if the former has acted illegally while the latter has not.”
With this single sentence, Longmore J must have shaken the confidence of every claimant lawyer looking to bring a class action.
“I think the class action lobby are on a hiding to nothing in the UK court,” said one litigation partner. “These are claimants who’ve suffered no actual loss – why should they be entitled to damages?”
But Irwin Mitchell’s lead partner on the case Jeremy Marshall is now planning to seek leave to appeal to the House of Lords. “This isn’t yet over, and the Court of Appeal’s given us the inkling that this should go to the Law Lords,” Marshall said.
It is understood that Irwin Mitchell is working on a contingency fee basis and therefore has a lot riding on the success of this case. If the firm wins in the Lords it will certainly be able to say that it won against the odds.
Claimant lawyers have for some time been calling on the Government to improve access to justice by modifying the class action framework and allowing more people to participate. Yet at every corner the lobby is curtailed by current UK case law. Only the case against the BA-Virgin cartel has been successful and that was largely because it was first brought in the US.
And while the defendant has the cash to pay for powerful lawyers and the claimant still scratches around for suitable funding, the situation will remain.
Subscribe to:
Posts (Atom)





